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Abstract Amphiphilic core–shell nanoparticle, which is
composed of a hydrophobic core and a branched poly-
ethylenimine (PEI) shell, has been designed and synthe-
sized as a novel gene delivery nanocarrier. In our previous
study, we demonstrated that the core–shell nanoparticle was
not only able to efficiently complex with plasmid DNA
(pDNA) and protect it against enzymatic degradation, but
also three times less cytotoxic, and threefold more efficient
in gene transfection than branched 25 kDa PEI. This paper
reports our further studies in the following three aspects: (1)
the ability of the PEI-based nanoparticles to deliver gene in
various mammalian cell lines; (2) intracellular distributions
of the nanoparticles and their pDNA complexes in HeLa
cells; and (3) incorporation of nuclear targeting agent into
the nanoparticle/pDNA complexes to enhance the nuclear
targeting ability. The PEI-based nanoparticles were able to
transfect both human and non-human cell lines and their
transfection efficiencies were cell-dependent. Within our
four tested cell lines (MCF-7, BEL 7404, C6 and CHO-K1),
gene transfer using PEI-based core–shell nanoparticles dis-
played gene expression levels comparable to, or even better
than, the commercial LipofectamineTM 2000. Confocal
laser scanning microscopy showed that the nanoparticles
and their pDNA complexes were effectively internalized
into the HeLa cells. The in vitro time series experiments
illustrated that both the nanoparticle/pDNA complexes and
PEI-based nanoparticles were distributed in the cytoplasmic
region after transfection for 10 and 60 min, respectively.
Nuclear localization was also observed in both samples
after transfection for 20 and 60 min, respectively. Incor-
poration of the high mobility group box 1 (HMGB1) protein
for nuclear targeting has also been demonstrated with a
simple approach: electrostatic complexation between the
PEI-based nanoparticles and HMGB1. In the in vitro
transfection study in MCF-7 cells, the expression level of
the firefly luciferase gene encoded by the pDNA increased
remarkably by up to eightfold when the HMGB1 protein
was incorporated into the nanoparticle/pDNA complexes.
Our results demonstrate that the PEI-based core–shell
nanoparticles are promising nanocarriers for gene delivery.
1 Introduction
Gene therapy is a promising approach to treat a variety of
genetic disorders [1, 2]. This approach is based on the
introduction of functional genes (e.g. gene segments, siR-
NA) to alter defective gene expression, and to restore nor-
mal metabolism, cellular and physiological responses of
patients [3, 4]. Up to now, the development of safe and
efficient gene delivery carriers for clinical use is still a
major challenge in human gene therapy. In the past two
decades, viral vectors have been widely applied in clinical
protocols. However, their applications are seriously ham-
pered by safety issues (i.e. the possibility of inducing severe
immune responses, and the provocation of mutagenesis)
[5–7], difficulty in their mass production and limitation in
gene loading capacity [5]. In the last decade, synthetic non-
viral vectors have been rapidly developed because of the
advancement in polymer science and nanotechnology.
These non-viral vectors are considered as alternatives to
overcome the adverse effects of viral vectors. Among the
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various types of non-viral vectors, cationic polymers such
as polylysine (PLL) [6, 7], polyethylenimine (PEI) [8–11],
polyamidoamine dendrimer (PAMAM) [12–15] and chito-
san [16–18] have received a great deal of attention owing to
their advantageous properties as compared with the viral
and cationic liposome-based vectors. For examples, they
are easy to prepare and to be chemically modified. They
also do not induce specific immune responses.
Many studies have suggested that branched PEI with an
average molecular weight of 25 kDa is one of the most
promising polymeric non-viral vectors because of its unique
chemical and structural properties [19]. It possesses high
cationic charge density, thus can effectively condense
nucleic acids into nano-sized particles through strong
electrostatic interaction. The resultant polyplexes can pro-
tect nucleic acids against enzymatic degradation, facilitate
interaction with cell surface and enhance cellular uptake
efficiency. After cellular internalization, the high amine
density of PEI can assist the endosomal escape of the
polyplexes from lysosomal compartments via the well-
known proton sponge effect. The gene cargos are then
released and expressed in a variety of mammalian cells [10].
Thus, PEI often possesses high transfection efficiency.
Despite the many advantages of the PEI-based vectors, they
have only achieved limited success, possibly because of
their high cytotoxicity and the broad particle size distribu-
tion of the resultant polyplexes [20]. Thus considerable
efforts have been made to reduce the cytotoxicity of PEI,
such as modifying PEI molecules to contain poly(ethylene
glycol) [21, 22], carboxylic acid group [23] and acid-
degradable amino ketal branches [24]. However, these PEI
modification methods usually involve multi-step syntheses
and tedious purification processes. They may also alter the
intrinsic properties of PEI (e.g. its sponge effect), thus
resulting in a lower transfection efficiency.
To address the PEI cytotoxicity problem and enhance
gene transfection efficiency, we have previously designed a
novel type of amphiphilic core–shell nanoparticle that is
composed of a poly(methyl methacrylate) (PMMA) core
and a branched PEI shell for gene delivery [25, 26]. The
PMMA–PEI nanocarrier is spherical in shape, monodis-
perse in aqueous medium and has a well-defined core–shell
nanostructure with a highly extended PEI shell in water.
The particle design is based on two main rationales: (1) to
reduce PEI cytotoxicity through immobilizing the PEI
molecules onto solid particles since the PEI toxicity is
caused by the multiple attachment of cationic PEI onto the
cell surface [27]; (2) to reduce the amount of PEI needed to
form complex nanoparticles with DNA molecules through
using preformed uniform core–shell nanoparticles con-
taining PEI shells. Our previous results have demonstrated
that this new type of PEI-based core–shell nanoparticles
could effectively condense nucleic acids and protect them
against enzymatic degradation. Most importantly, they
were three times less cytotoxic than the branched PEI, and
three times more efficient in transfection. Furthermore,
loading plasmid DNA (pDNA) onto the uniform PMMA–
PEI nanocarriers gave a much better control over size
distribution than the direct complexation between PEI
polymer and pDNA, thus improving the pharmacokinetic
and therapeutic efficacy of the delivered nucleic acids.
As part of our continuous effort to develop this novel
type of PEI-based core–shell nanocarrier, we herein report
our studies on gene transfer ability of the PMMA–PEI
nanocarrier in various mammalian cells and intracellular
path of the nanocarrier in the HeLa cell. In addition, the
targeting ability of the PMMA–PEI nanocarrier has also
been demonstrated through the incorporation of the high
mobility group box 1 protein (HMGB1), a nuclear targeting
protein.
2 Experimental
2.1 Materials
Branched PEI with average molecular weight of 25 kDa
(water-free) was obtained from Aldrich. Methyl methacry-
late (Aldrich) was purified by washing three times with 10%
sodium hydroxide solution and then with deionized water
until the pH of the water layer dropped to 7. It was further
purified by vacuum distillation. tert-Butyl hydroperox-
ide (70% solution in water) was obtained from Acros.
Poly(aspartic acid) (pAsp) and fluorescein isothiocyanate
(FITC) isomer 1 were purchased from Sigma-Aldrich.
Luciferase Assay System and plasmid pGL3-Control vector
encoding the firefly luciferase reporter gene were purchased
from Promega. The plasmid was propagated in Escherichia
coli (JM109) and was purified by QIA Spin Miniprep Kit
(Qiagen). High mobility group box protein (HMGB1) was
extracted and purified from pig thymus according to the
methodology of Goodwin et al. [28]. LipofectamineTM
2000, all cell culture media and sera were purchased from
Invitrogen. Label IT TM-Rhodamine Nucleic Acid
Labeling Kit was purchased from Mirus.
2.2 Preparation and Characterization of PMMA–PEI
Core–Shell Nanoparticles
The PMMA–PEI amphiphilic core–shell nanoparticles
were prepared according to our previously described
method [25]. After polymerization, the crude particle dis-
persion was purified through repeated centrifugations and
decantations with de-ionized water until the conductivity of
the supernatant was similar to that of the water used.
Particle size and size distribution were measured on a
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Coulter LS 230 Particle Size Analyzer. zeta-Potential of
the PMMA–PEI nanoparticles were determined with
a Malvern Zetasizer 3000HS (Malvern, UK) in a 1 mM
NaCl aqueous solution. The nanostructures of the particles
were observed with a JEM 100 CX transmission electron
microscope (TEM) with an accelerating voltage of 100 kV.
The dried PMMA–PEI nanoparticles on a carbon-coated
grid were treated with a small drop of 2% phosphotungstic
acid (PTA) for an appropriate time. The morphology of the
particles was also observed with a JEOL JSM 6335F field
emission scanning electron microscope (SEM). Samples
were prepared by spreading a drop of dilute particle dis-
persion on a glass surface and dried in a dust-free envi-
ronment at room temperature. The dried specimen was then
coated under vacuum with a thin layer of gold to a depth of
5 A˚.
2.3 Formation of Nanoparticle/pDNA, PEI/pDNA,
pDNA/HMGB1 and Nanoparticle/pDNA/HMGB1
Complexes
pGL3-Control vector was used as the pDNA for studying
the complexing abilities of various gene carriers. Nano-
particle/pDNA and PEI/pDNA complexes were prepared
by mixing various amounts of nanoparticles (ranging from
0 to 800 lg) and PEI polymer (ranging from 0 to 196 lg)
with 0.3 lg of pDNA, and allowed to incubate at room
temperature for 30 min. The complexing ratio is expres-
sed as the molar fraction of the amino group in PEI to
the phosphate group in pDNA (N/P ratio). Besides,
pDNA/HMGB1 and nanoparticle/pDNA/HMGB1 com-
plexes were prepared by mixing 0.1 lg of HMGB1 pro-
tein with the pDNA or nanoparticle/pDNA complexes,
and incubated at room temperature for 20 min. After the
incubation, all complexes were analyzed by 0.8% agarose
gel electrophoresis.
2.4 Release of pDNA from Nanoparticle/pDNA
and Nanoparticle/pDNA/HMGB1 Complexes
The ability to release pDNA from the nanoparticle/pDNA
and nanoparticle/pDNA/HMGB1 complexes and the
integrity of the released pDNA were investigated by the
addition of pAsp. The pAsp molecules were mixed with
the complexes in a pAsp to pDNA molar ratio of 100. The
mixture was then incubated at room temperature for 2 h
and was analyzed by 0.8% agarose gel electrophoresis.
2.5 Cell Culture
The human cell lines HeLa, MCF-7, BEL 7404 and the
non-human cell lines C6, CHO-K1 were cultured in low
glucose Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% (v/v) fetal bovine serum (FBS),
100 units/mL penicillin and 100 lg/mL streptomycin (P/S)
at 37C in a humidified atmosphere containing 5% CO2.
2.6 In Vitro Transfection Study
For the transfection studies of PMMA–PEI nanoparticles
and PEI polymer, cells were seeded in 6-well plates with
4 9 105 cells per well. After overnight incubation, cells
were treated with nanoparticle/pDNA and PEI/pDNA
complexes prepared at N/P ratios of 3, 5, 8, 10 and 15. All
samples were prepared in a serum-free medium and incu-
bated with cells for 4 h. Subsequently, medium in each
well was replaced with fresh complete growth medium, and
the cells were collected after incubation for another 32 h.
For the transfection study of nanoparticle/pDNA/
HMGB1 complexes, cells were seeded in 24-well plates
with 1.2 9 105 cells per well. They were then treated with
the nanoparticle/pDNA/HMGB1 complexes for 4 h, and
collected after incubation for another 20 h.
The expression level of the firefly luciferase reporter
gene of the pGL3-Control plasmid was analyzed by
Luciferase Assay System (Promega). Cells were collected
according to the manufacturer’s instruction and the relative
luminescence units (RLU) were measured with a Turner
Design TD-20/20 Luminometer (Promega). In all studies,
LipofectamineTM 2000 was used as a control and Lipo-
fectamine/pDNA were prepared according to the manu-
facturer’s instruction.
2.7 Intracellular Trafficking of PMMA–PEI
Nanoparticles and Nanoparticle/pDNA Complexes
by Confocal Laser Scanning Microscopy
The intracellular paths of the PMMA–PEI nanoparticles
and their pDNA complexes were studied by the confocal
laser scanning microscopy. In this study, the nanoparticles
were labeled with FITC isomer 1 according to our previ-
ously described method with minor modification [29]. The
nanoparticles were incubated with FITC in borate buffer
(0.1 M, pH 8.5) at nanoparticle to FITC ratio of 10–1 (w/w)
for 4 h at room temperature. The unreacted FITC mole-
cules were removed by dialysis against 1 L of deionized
distilled water (1,000x volume of the labeling reaction) for
16 h. For the dual fluorescent labeling experiment, the
pDNA was labeled with tetramethyl-rhodamine (TM-rho-
damine) according to the instruction provided with the
Label IT TM-Rhodamine Nucleic Acid Labeling Kit.
HeLa cells were seeded in 8-well chamber slides with
4 9 104 cells per well and incubated overnight. The cells
were then treated with fluorescent labeled nanoparticles
and nanoparticle/pDNA complexes (with N/P ratio of 5).
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At various time points (10 min to 4 h), the cells were fixed
with 4% (v/v) paraformaldehyde in PBS for 30 min and
visualized under a confocal microscope (LSM 510 META,
Carl Zeiss Inc.) with an argon laser (488 nm excitation)
and a 505–530 nm band-pass filter. For the dual fluores-
cence images, the TM-rhodamine signal was obtained with
a helium/neon laser (543 nm) and a band-pass filter of
576–640 nm.
3 Results and Discussion
3.1 Preparation and Characterization of PMMA-PEI
Core–Shell Nanoparticles
The PMMA–PEI amphiphilic core–shell nanoparticles were
prepared according to our previously described procedures
[25]. Methyl methacrylate (MMA) monomer was polymer-
ized with cationic branched PEI (25 kDa) in a weight ratio of
1:2. After purifying the resultant nanoparticles, the actual
compositions of the nanoparticles were determined, and they
contained 29% PEI and 71% PMMA. The PMMA–PEI
nanoparticles displayed positive surface charges in the range
of ?35 to ?40 mV as measured in a 1 mM of NaCl solution.
The number and volume average particle diameters were 103
and 110 nm, respectively, with very narrow particle size
distribution [polydispersity index (Dv/Dn) = 1.07]. SEM
image shows that the nanoparticles were spherical and highly
uniform (Fig. 1). Through selective staining of the particles
with a diluted PTA solution for an appropriate time, the core–
shell nanostructure of the particles was clearly revealed with
the TEM (inset of Fig. 1).
3.2 Performance of the Nanoparticles as pDNA Carrier
3.2.1 Formation of Nanoparticle/pDNA Complexes
DNA condensation onto the gene carrier is the first step in
gene delivery. In this study, the pDNA condensation
capability of our core–shell nanoparticles was compared
with the branched 25 kDa PEI polymer by agarose gel
electrophoresis. Figure 2 (upper panel) shows that both
PMMA–PEI nanoparticles and PEI polymer could effec-
tively condense pDNA and complete pDNA retardation
occurred at the N/P ratio of 2. However, at lower N/P
ratios, the PMMA–PEI nanoparticles are far more efficient
than the PEI. For example, at the N/P ratio of 1, much less
DNA was left uncomplexed with the nanoparticle than the
PEI alone. This is shown by the much weaker intensity of
the uncomplexed pDNA band from the nanoparticle-based
complexation than that of PEI. These results indicate that
the PMMA–PEI nanoparticles have a much better DNA
complexing capability than the PEI polymer.
3.2.2 Gene Transfection Mediated by PMMA–PEI
Nanoparticles
The pGL3-Control pDNA used to complex with the
nanoparticles carries the firefly luciferase gene. The
transfection efficiency can therefore be assayed by mea-
suring the firefly luciferase activity in the target cells. In
Fig. 1 SEM micrograph of PMMA–PEI core–shell nanoparticles.
Inset TEM micrograph of nanoparticles showing well-defined PMMA
cores (lighter part) and PEI shells (darker region)
Fig. 2 Upper panel Agarose gel retardation study on the formation of
nanoparticle/pDNA and PEI/pDNA complexes at various N/P ratios
(ranging from 0.5 to 5). Lower panel Comparison of PMMA–PEI
nanoparticles and PEI mediated transfection at various N/P ratios in
HeLa cells. 2 lg of pGL3-Control plasmid was used for the
preparation of each complex, and the luciferase activities were
measured 36 h after transfection
Page 4 of 10 Biointerphases (2012) 7:16
123
our in vitro transfection experiment, HeLa cells were used
and the transfection efficiency was determined by the
firefly luciferase enzyme activity expressed in RLU.
We have tested the effect of various N/P ratios on the
transfection efficiency. Since complete complexation
occurred at the N/P ratio of 2, we started with the N/P ratio
of 3. At this N/P ratio, the gene transfer ability of the
PMMA–PEI nanoparticles was far more efficient than that
of the PEI polymer (Fig. 2, lower panel). At the N/P ratio
of 5, the transfection efficiency of the nanoparticle/pDNA
complexes was about twice of that at the N/P ratio of 3.
This is probably due to the increase in the amine content in
the nanoparticle/pDNA complexes. The higher amine
content provides a higher buffering capacity to facilitate
the endosomal escape of the pGL3-Control plasmid into
the cytoplasm. As more pDNA are in the cytoplasm, more
could be transported from the cytoplasm into the nucleus
for gene expression. However, further increasing the N/P
ratio from 5 to 15 did not show improvement in the
transfection efficiency but a decline instead. This may be
due to the fact that excess positive charges on the nano-
particle/pDNA complex surface may lead to distortion of
the cell membrane and cell lysis. Therefore, the optimal
N/P ratio for PMMA–PEI nanoparticle mediated transfec-
tion in HeLa cells is 5 and this N/P ratio gave the best
balance between the endosomolytic activity and cellular
toxicity of the PEI molecules present on the surface of the
nanoparticles.
In the range of N/P ratio we have tested (3–15), the
PMMA–PEI nanoparticles always demonstrate a higher
transfection efficiency than the branched PEI polymer. This
is probably due to the fact that the PEI polymer is more toxic
to the cells than the PMMA–PEI nanoparticles [26]. With
more healthy viable cells present, higher firefly luciferase
enzyme activity would obviously be detected. The above
findings demonstrate clearly that the PMMA–PEI nano-
particle system is a much better system than the PEI poly-
mer, at least in in vitro transfection experiments.
3.2.3 PMMA–PEI Nanoparticle Mediated Transfection
in Human and Non-Human Cell Lines
In in vitro transfection studies, the commercially available
LipofectamineTM 2000 is commonly used. In order
to compare the transfection efficiency between the
PMMA–PEI nanoparticles and the commercially available
LipofectamineTM 2000, another four mammalian cell lines,
MCF-7, BEL 7404, C6 and CHO-K1, were used. The first
two cell lines are human carcinoma cells while the other
two are rat brain cells and hamster ovary cells, respec-
tively. Results in Fig. 3 show that the PMMA–PEI nano-
particles could transfect all four cell lines and in each of
these four cell lines, the optimal transfection efficiency
occurred at the N/P ratio of either 5 or 8. In the MCF-7 and
the CHO-K1 cells, the PMMA–PEI nanoparticles were far
more efficient than the lipofectamine while in the other two
cell lines, the PMMA–PEI nanoparticles were less efficient
then the lipofectamine. These results show that the
PMMA–PEI nanoparticles are as efficient as, if not more
efficient than, the commercially available lipofectamine
and they are efficient in transfecting both human and non-
human mammalian cells. We therefore believe that this
PEI-based nanoparticle has the potential to be used as a
gene carrier in both human and non-human systems.
3.3 Intracellular Trafficking of PMMA–PEI
Nanoparticles and Nanoparticle/pDNA Complexes
In order to better understand the mechanism of PMMA–-
PEI mediated transfection, fluorescent labels and imaging
techniques were used to track the intracellular paths and
distributions of the nanoparticles and their pDNA
complexes.
3.3.1 Intracellular Trafficking of PMMA–PEI
Nanoparticles
Confocal laser scanning microscopy was employed to track
the post-transfection of FITC-labeled PMMA–PEI nano-
particles. Figure 4 shows the confocal laser scanning
microscopic images of HeLa cells at various post-trans-
fection time points. At 20 min after transfection, only very
weak FITC signals were detected and the green fluores-
cence was just visible as silhouette. It indicates that some
of the labeled PMMA–PEI nanoparticles were starting to
interact with the cell surface. The fluorescence appeared as
patches, suggesting that the PMMA–PEI nanoparticles
were aggregating on specific areas of the plasma mem-
brane. At 1 h after transfection, the green fluorescence
signals were mainly observed in the cytoplasmic region of
the HeLa cells. This indicates that the FITC-labeled
nanoparticles were internalized into the cells, and some had
even migrated into the nuclear region (as indicated by the
arrows). After 2 h post-transfection, more and more FITC-
labeled nanoparticles were found to have been taken up by
the cells, and endocytotic vesicles became observable.
Nucleoli in the nuclear region had also lightened up and
this is a clear evidence of nuclear localization of the
PMMA–PEI nanoparticles.
3.3.2 Intracellular Trafficking of Nanoparticle/pDNA
Complexes
Figure 5 shows that the PMMA–PEI nanoparticles after
complexing with pDNA were internalized by the cells at
a faster rate than the nanoparticles alone. At 10 min
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post-transfection, green fluorescence signals were already
observable in the cytoplasm of HeLa cells. From 10 to
40 min, higher and higher fluorescence intensities were
observed inside the cells, indicating the presence of
increasing FITC-labeled nanoparticle/pDNA complexes in
the HeLa cells. At the same time, the first evidence of
fluorescence inside the nucleus was observed at 20 min
after transfection. Cell population with nuclear fluores-
cence had further increased at 40, 50 and 60 min. After 4 h
post-transfection, the FITC-labeled nanoparticle/pDNA
complexes were observable in both the cytoplasmic and
nuclear regions in most of the cells. Further study by using
Fig. 3 PMMA–PEI nanoparticle mediated transfection in human
breast adenocarcinoma cell line (MCF-7), human liver carcinoma cell
line (BEL 7404), rat brain glial cell line (C6) and Chinese hamster
ovary cell line (CHO-K1). 2 lg of pGL3-Control plasmid was used
for the preparation of each complex, and the luciferase activity was
measured 36 h after transfection
Fig. 4 Cellular internalization and nuclear localization of FITC-labeled PMMA–PEI nanoparticles in HeLa cells. Cells were incubated with the
nanoparticles for 20 min, 1 h and 2 h, respectively. Cells with nuclear fluorescence are indicated by the arrows
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dual-fluorescent labeling, in which the pDNA was labeled
with TM-rhodamine, confirmed that the pDNA remained
bound to the nanoparticle even at 4 h post-transfection. The
confocal laser micrograph is shown in Fig. 6. All these
results suggest that the cellular internalization and nuclear
localization rates of the PMMA–PEI nanoparticles are
actually enhanced with the association of the pDNA. This
may attribute to the fact that the nanoparticle/pDNA
complexes have a smaller diameter than the PMMA–PEI
nanoparticles as a result of electrostatic neutralization
between the negatively charged pDNA and the positively
charged PEI shell. This effect has been demonstrated in our
previous study [26]. For example, at the N/P ratio of 5, the
complexed nanoparticles have a reduction in their
diameters from 146 to 124 nm. We believe that the smaller
particle size of the complexes is the key factor in the
increase in the cellular internalization and the nuclear
localization efficiency.
3.4 Nanoparticle/pDNA Complexes Containing
Nuclear Targeting Protein
For non-viral gene delivery carriers, the nuclear membrane
is actually the major barrier for efficient gene transfer.
Quantitative cytoplasmic microinjection studies have
demonstrated that only 0.1% of the naked pDNA could
reach the nucleus where the transgene is transcribed and
subsequently expressed [30]. Even for the well studied
Fig. 5 Cellular internalization and nuclear localization of FITC-
labeled nanoparticle/pDNA complexes in HeLa cells. Cells were
incubated with the complexes for 10 min to 4 h. Cells with nuclear
fluorescence (indicated by arrows) were observed at 10–40 min. After
50 min of incubation, most of the cells exhibited nuclear accumu-
lation of the FITC-labeled complexes
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PEI/pDNA polyplexes, which show nuclear accumulation
property, only 1% of the pDNA can be transported into the
nucleus [31]. In order to overcome the nuclear membrane
barrier and to further improve the PMMA–PEI nanoparticle
gene delivery system, the nuclear protein, HMGB1 was
combined with the nanoparticle/pDNA complex.
3.4.1 Incorporation of Nuclear Protein
into the Nanoparticle/pDNA Complex
In this part of study, the nuclear protein HMGB1 was
added as an additional component in the existing nano-
particle/pDNA gene delivery system. The nuclear protein
HMGB1 contains two homologous DNA binding motifs
(HMG box A and B) and a polyacidic tail [32]. It also
contains two nuclear localization signals (NLSs) for con-
trolled nuclear transport [33, 34]. The rationale for our
design is to use the HMGB1 protein as a nuclear targeting
agent. Being an ampholyte, the HMGB1 protein has the
ability to interact with both the negatively charged pDNA
and the positively charged PMMA–PEI nanoparticle sim-
ply by electrostatic interaction. Introduction of HMGB1 to
the nanoparticle/pDNA complexes can result in the for-
mation of nanoparticle/pDNA/HMGB1 complexes through
interaction between the amine group of the PEI shell and
the terminal acidic domain of the HMGB1 protein. The
Fig. 6 Confocal laser scanning microscopic image of HeLa cells
after 4 h post-transfection with dual-fluorescent labeled nanoparticle/
pDNA complexes. The red signals (pDNA) were all co-localized with
the green signals (PMMA–PEI), indicating the presence of pDNA
with the nanoparticles
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resultant nanoparticle/pDNA/HMGB1 complexes should
have the NLSs present on the surface of the complex to
facilitate the nuclear import process.
We have shown that the presence of the HMGB1 protein
does not affect the complexing capability of the PMMA–
PEI nanoparticles. With (Fig. 7, left panel, lane 5) or
without the inclusion of HMGB1 (lane 2), pDNA molecules
were completely complexed to the PMMA–PEI nanoparti-
cles at the N/P ratio of 5. Furthermore, all the pDNA were
released from the nanoparticle/pDNA/HMGB1 complexes
when incubated with pAsp in a pAsp/pDNA molar ratio of
100. The released pDNA remained intact in the supercoiled
form (lane 6). It indicates that the inclusion of HMGB1 in
the nanoparticle gene delivery system does not affect the
integrity of the DNA nor the ability of the system to release
the complexed DNA.
It was also found that the pDNA released from the
nanoparticle/pDNA/HMGB1 complexes displayed a
slower electrophoretic mobility than the naked pDNA (lane
1), and the pDNA released from the nanoparticle/pDNA
complexes (lane 3), but similar to that of the pDNA/
HMGB1 complexes (lane 4). This finding is actually rea-
sonable as HMGB1 is a well known DNA binding chro-
mosomal protein and it is expected to bind the pDNA even
when the pDNA is released from the PMMA–PEI nano-
particle. The results suggest that the pDNA may still retain
its nuclear targeting ability by HMGB1 binding even if the
nanoparticle is disassembled during the gene transfer pro-
cess. The binding effect may help to shuttle the exogenous
gene into the nucleus for gene expression.
3.4.2 Transfection Efficiency of the Nanoparticle/pDNA/
HMGB1 Complexes
The effectiveness of including HMGB1 in the PMMA–PEI
nanoparticle gene delivery system was investigated by in
vitro transfection of MCF-7 cells. The nanoparticle/pDNA/
HMGB1 complexes were prepared at various N/P ratios,
but with a fixed pDNA/HMGB1 weight ratio of 3, based on
the optimal ratio reported by Kato et al. [35] and Namiki
et al. [36] in their in vitro and in vivo liposome mediated
transfection studies. For comparison, same N/P ratios of
nanoparticle/pDNA complexes with and without HMGB1
were studied. LipofectamineTM 2000 and pDNA/HMGB1
complexes were used as controls. Four N/P ratios of 2, 5, 8
and 10 were tested and it was found that in all four ratios,
much higher luciferase activities were observed with the
inclusion of HMGB1 (Fig. 7, right panel). These results
indicate that HMGB1 can significantly enhance the effi-
ciency of the PMMA–PEI nanoparticle gene delivery sys-
tem. The most remarkable result was observed at the N/P
ratio of 5 in which the system has its highest transfection
efficiency and it was more than eightfold higher than that
of just the PMMA–PEI nanoparticles. It is known that the
HMGB1 protein binds to the RAGE (receptor for advanced
glycation endproducts) presented on the cell surface [37]
and has NLSs [33]. Therefore, it is reasonable to suggest
that with the inclusion of HMGB1 on the nanoparticle/
pDNA complex, cellular uptake is facilitated via ligand–
receptor interaction and nuclear localization is enhanced
via the NLS.
Fig. 7 Left panel Agarose gel analysis for the formation of
complexes at the N/P ratio of 5, and the release of pDNA from
complexes using pAsp at a pAsp/pDNA molar ratio of 100.
Right panel Transfection efficiencies of nanoparticle/pDNA/HMGB1
complexes and nanoparticle/pDNA complexes at various N/P ratios in
MCF-7 cells. 0.4 lg of pGL3-Control plasmid was used for the
preparation of each complex, and the luciferase activities were
measured 24 h after transfection
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4 Summary and Conclusions
This work described the use of amphiphilic core–shell
nanoparticle consisting of poly(methyl methacrylate) core
with branched PEI shell as a versatile gene carrier. Results
based on the agarose gel retardation assay and in vitro
transfection study showed that our PMMA–PEI core–shell
nanoparticle has a better DNA condensation capacity and
higher gene transfer efficiency than the branched 25 kDa
PEI. The in vitro transfection experiments also suggested
that the PMMA–PEI nanoparticles could be used in
transfection of both human and non-human cells (e.g.
MCF-7, BEL 7404, C6 and CHO-K1), and their gene
expression levels were higher than, or at least comparable
to the commercially available transfection agent, Lipo-
fectamineTM 2000. Confocal laser scanning microscopy
illustrated that the PMMA–PEI nanoparticle and its pDNA
complexes were effectively internalized by HeLa cells, and
eventually localized in the nuclear region of the cells. The
inclusion of nuclear targeting agent, HMGB1 protein with
the nanoparticle/pDNA complexes significantly enhanced
the foreign gene expression by up to eightfold. As the
PMMA–PEI nanoparticle can effectively transfect different
cell lines and can be modified with targeting agent, this
PEI-based amphiphilic core–shell nanoparticle is an effi-
cient and versatile nanocarrier for gene delivery.
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